牛牛AI助理已提取核心訊息
On February 15, 2024, Tonix Pharmaceuticals Holding Corp. held a Special Meeting where shareholders voted on two key proposals. The meeting saw participation from shareholders representing 33.9% of the common stock outstanding as of the record date, December 21, 2023. The first proposal, which passed, was to approve the issuance of up to 162,162,162 shares of common stock upon the exercise of outstanding Series C and Series D warrants issued to institutional investors during a December 22, 2023 offering. This issuance is in compliance with The Nasdaq Stock Market LLC Listing Rule 5635(d). The second proposal, also approved, allowed for the adjournment of the Special Meeting to solicit additional proxies if necessary to approve the first proposal. The results of the votes were detailed in the Company's proxy statement filed on January 8, 2024.
On February 15, 2024, Tonix Pharmaceuticals Holding Corp. held a Special Meeting where shareholders voted on two key proposals. The meeting saw participation from shareholders representing 33.9% of the common stock outstanding as of the record date, December 21, 2023. The first proposal, which passed, was to approve the issuance of up to 162,162,162 shares of common stock upon the exercise of outstanding Series C and Series D warrants issued to institutional investors during a December 22, 2023 offering. This issuance is in compliance with The Nasdaq Stock Market LLC Listing Rule 5635(d). The second proposal, also approved, allowed for the adjournment of the Special Meeting to solicit additional proxies if necessary to approve the first proposal. The results of the votes were detailed in the Company's proxy statement filed on January 8, 2024.
2024年2月15日，Tonix Pharmicals Holding Corp. 舉行了一次特別會議，股東們對兩項關鍵提案進行了投票。截至記錄日期，即2023年12月21日，佔已發行普通股33.9％的股東參加了會議。第一項提案獲得通過，是批准在行使2023年12月22日發行期間向機構投資者發行的未償還的C系列和D系列認股權證後，發行最多162,162股普通股。本次發行符合納斯達克股票市場有限責任公司上市規則5635（d）。第二項提案也獲得通過，允許特別會議休會，以便在必要時徵集更多的代理人來批准第一項提案。公司於2024年1月8日提交的委託書詳細介紹了投票結果。
2024年2月15日，Tonix Pharmicals Holding Corp. 舉行了一次特別會議，股東們對兩項關鍵提案進行了投票。截至記錄日期，即2023年12月21日，佔已發行普通股33.9％的股東參加了會議。第一項提案獲得通過，是批准在行使2023年12月22日發行期間向機構投資者發行的未償還的C系列和D系列認股權證後，發行最多162,162股普通股。本次發行符合納斯達克股票市場有限責任公司上市規則5635（d）。第二項提案也獲得通過，允許特別會議休會，以便在必要時徵集更多的代理人來批准第一項提案。公司於2024年1月8日提交的委託書詳細介紹了投票結果。
有用
沒用